All these findings facilitate our understanding of the potential of GNUV201 as an anti-cancer antibody with novel properties and provide a novel targetable region for the development of anti-PD-1 antibodies for tumor immunotherapy. This evidence concerns the gene PDCD1 and neoplasm.